With the targeted drug treatments that are now available for CML most people do very well on treatment.
Survival depends on many factors. No one can tell you exactly how long you will live.
These are general statistics based on large groups of people. Remember, they can’t tell you what will happen in your individual case.
No UK-wide statistics are available for CML survival.
These statistics are for people with CML in England, diagnosed between 2008 and 2010. They come from the National Cancer Intelligence Network.
Generally for CML more than 70 out of 100 men (more than 70%) and almost 75 out of 100 women (almost 75%) will survive their leukaemia for 5 years or more after they are diagnosed. This is for all ages. Younger people tend to have a better outlook than older people.
For people aged between 15 and 64, almost 90 out of 100 (almost 90%) will survive their leukaemia for 5 years or more after they are diagnosed.
For people aged 65 or over, more than 40 out of 100 (more than 40%) will survive their leukaemia for 5 years or more.
National Cancer Intelligence Network. Trends in incidence and outcome for haematological cancer in England: 2001 - 2010
Public Health England, 2014
These statistics are for relative survival. Relative survival takes into account that some people will die of causes other than cancer. This gives a more accurate picture of cancer survival.
What affects survival
Your outlook depends on your response to treatment and how well you tolerate it.
Most patients are diagnosed when they are in chronic phase but can still respond well if they are diagnosed in accelerated or blast phase.
CML is usually a slowly developing condition and treatment can keep it under control for many years. Targeted cancer drugs (tyrosine kinase inhibitors TKI) work very well.
People can go into remission for many years. This is when the disease isn’t active, you don't have symptoms and the full blood count is normal. CML may be measured at very low molecular levels in the blood and different levels of molecular remission can be achieved. If the molecular levels of CML increase then a different TKI can be given.
If targeted cancer drugs don't work, you’re likely to have intensive treatment with a stem cell or bone marrow transplant.
CML that has entered the blast phase is more difficult to manage. Treatment can sometimes get it back into chronic phase, where it’s not so difficult to keep under control. If CML in blast phase doesn’t respond to treatment, unfortunately you are more likely to live for months, rather than years.
About these statistics
The term 5 year survival doesn't mean that you will only live for 5 years. It relates to the number of people who are still alive 5 years after their diagnosis of cancer.
Doctors continue to try to improve the treatments and outlook for people with CML through clinical trials.
For more in-depth information about survival and CML, go to Cancer Research UK's Cancer Statistics section.